Phase 1 study of CS-1008 [tigatuzumab], a humanized monoclonal antibody targeting death receptor 5 (DR5), administered weekly to patients with advanced solid malignancies and lymphomas (without leukemic component)
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Tigatuzumab (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; Biomarker
- 21 Jun 2007 New trial record.